Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Interest Expenses (2024 - 2025)

OptimizeRx's Interest Expenses history spans 6 years, with the latest figure at $1.2 million for Q3 2025.

  • For Q3 2025, Interest Expenses fell 24.28% year-over-year to $1.2 million; the TTM value through Sep 2025 reached $5.6 million, up 22.12%, while the annual FY2024 figure was $6.2 million, 323.66% up from the prior year.
  • Interest Expenses for Q3 2025 was $1.2 million at OptimizeRx, down from $1.6 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $1.6 million in Q2 2025 and bottomed at $1.2 million in Q3 2025.